Down syndrome and leukemia: from basic mechanisms to clinical advances

André Baruchel; Jean Pierre Bourquin; John Crispino; Sergi Cuartero; Henrik Hasle; Johann Hitzler; Jan Henning Klusmann; Shai Izraeli; Andrew A. Lane; Sébastien Malinge; Karen R. Rabin; Irene Roberts; Sandra Ryeom; Sarah K. Tasian; Elvin Wagenblast

doi:10.3324/haematol.2023.283225

Down syndrome and leukemia: from basic mechanisms to clinical advances

André Baruchel, Jean Pierre Bourquin, John Crispino, Sergi Cuartero^*, Henrik Hasle, Johann Hitzler, Jan Henning Klusmann, Shai Izraeli, Andrew A. Lane, Sébastien Malinge^*, Karen R. Rabin, Irene Roberts, Sandra Ryeom^*, Sarah K. Tasian, Elvin Wagenblast

^*Corresponding author for this work

Department of Clinical Medicine - Department of Paediatrics

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

12 Citations (Scopus)

Abstract

Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the Jérôme Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.

Original language	English
Journal	Haematologica
Volume	108
Issue	10
Pages (from-to)	2570-2581
Number of pages	12
ISSN	0390-6078
DOIs	https://doi.org/10.3324/haematol.2023.283225
Publication status	Published - Oct 2023

Access to Document

10.3324/haematol.2023.283225Licence: CC BY-NC

Cite this

@article{b7eba493f435408e836bdf0123ff286c,

title = "Down syndrome and leukemia: from basic mechanisms to clinical advances",

abstract = "Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the J{\'e}r{\^o}me Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.",

author = "Andr{\'e} Baruchel and Bourquin, {Jean Pierre} and John Crispino and Sergi Cuartero and Henrik Hasle and Johann Hitzler and Klusmann, {Jan Henning} and Shai Izraeli and Lane, {Andrew A.} and S{\'e}bastien Malinge and Rabin, {Karen R.} and Irene Roberts and Sandra Ryeom and Tasian, {Sarah K.} and Elvin Wagenblast",

year = "2023",

month = oct,

doi = "10.3324/haematol.2023.283225",

language = "English",

volume = "108",

pages = "2570--2581",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

TY - JOUR

T1 - Down syndrome and leukemia

T2 - from basic mechanisms to clinical advances

AU - Baruchel, André

AU - Bourquin, Jean Pierre

AU - Crispino, John

AU - Cuartero, Sergi

AU - Hasle, Henrik

AU - Hitzler, Johann

AU - Klusmann, Jan Henning

AU - Izraeli, Shai

AU - Lane, Andrew A.

AU - Malinge, Sébastien

AU - Rabin, Karen R.

AU - Roberts, Irene

AU - Ryeom, Sandra

AU - Tasian, Sarah K.

AU - Wagenblast, Elvin

PY - 2023/10

Y1 - 2023/10

N2 - Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the Jérôme Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.

AB - Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the Jérôme Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.

UR - http://www.scopus.com/inward/record.url?scp=85174080124&partnerID=8YFLogxK

U2 - 10.3324/haematol.2023.283225

DO - 10.3324/haematol.2023.283225

M3 - Review

C2 - 37439336

AN - SCOPUS:85174080124

SN - 0390-6078

VL - 108

SP - 2570

EP - 2581

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Down syndrome and leukemia: from basic mechanisms to clinical advances

Abstract

Access to Document

Other files and links

Fingerprint

Cite this